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In a recent issue of the New England 
Journal of Medicine, Srivastava and col-
leagues reported the presence of antibodies 
to the inward rectifying potassium channel 
4.1 (anti-KIR4.1) in MS (7).
The authors observed that purified 
serum immunoglobulin G (IgG) from 
MS patients, but not from patients with 
other neurological diseases, bound to a 
glial protein in human brain sections. 
Human brain lysate precipitated with IgG 
from MS patients revealed KIR4.1 to be 
the target antigen. Anti-KIR4.1 antibod-
ies were found in serum samples of 47% 
of MS patients, 1% of patients with other 
neurologic diseases and in none of the 
samples from healthy controls. Moreover, 
anti-KIR4.1 antibodies were detected in the 
CSF of most MS patients tested. In all MS 
patients harboring anti-KIR4.1 antibodies, 
IgG isotypes capable of activating the com-
plement cascade were found. Twenty-four 
hours after injection of anti-KIR4.1 anti-
bodies and complement into the cisternae 
magnae of wild-type mice, the authors 
observed decreased expression of KIR4.1 
and glial fibrillary acidic protein (GFAP), 
a protein expressed by astrocytes.
In their study, Srivastava and colleagues 
provide data in support of autoantibod-
ies to KIR4.1 as important mediators of 
inflammation and tissue damage in MS. 
Their work favors an autoimmune process 
to be the underlying cause of MS, since 
specific autoantibodies capable of causing 
structural damage in normal animals were 
present in a large number of MS patients. 
While classical features of MS lesion pathol-
ogy such as demyelination, axonal loss, and 
microglial activation were not observed, the 
authors report evidence for cytotoxicity 
toward astrocytes.
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Multiple sclerosis (MS) is an inflamma-
tory demyelinating disease of the central 
nervous system (CNS); its etiology and 
pathophysiology remain incompletely 
understood. Aberrant activation of the 
immune system is believed to play a cen-
tral role in MS (1). Despite being labeled an 
autoimmune condition, MS does not fulfill 
the criteria of a classic autoimmune disease 
(2). Myelin-reactive antibodies have been 
detected in serum and cerebrospinal fluid 
(CSF) samples of MS patients, their speci-
ficity and contribution to the disease pro-
cess, however, remains a matter of debate. 
The original concept behind using the B-cell 
depleting agent Rituximab in MS was based 
upon the idea that eliminating autoan-
tibodies may improve clinical outcome. 
While Rituximab reduces disease activity 
and is associated with a rapid decreases in 
both B and T cells (3), antibody titers are 
essentially not affected (4). It was therefore 
proposed that elimination of B cells may 
actually hamper cytokine-mediated activa-
tion of T cells and results in decreased T 
cell trafficking across the blood-brain bar-
rier (5). However, modifying the humoral 
immune response through plasma exchange 
has shown clinical benefit in certain cases 
of very active MS (6), suggesting a central 
role of soluble mediators such as cytokines, 
antibodies, and complement in MS.
Until recently, neuromyelitis optica 
(NMO), an inflammatory disease of the 
CNS which presents with severe visual fail-
ure and extensive transverse myelitis was 
regarded as a variant of MS. Identification 
of antibodies against the astrocyte water 
channel protein aquaporin 4 (AQP4) has 
led to general acceptance that this condi-
tion is distinct from MS (8). The work by 
Srivastava and colleagues will foster the 
discussion of how closely MS and NMO 
are indeed related. Analogous to the 
pathology described by Srivastava and col-
leagues, human anti-AQP4 antibodies can 
induce CNS lesions with loss of AQP4 and 
GFAP in animals through activation of 
complement (9). Co-localization of Kir4.1 
and AQP4 promotes water permeability 
in response to fluctuations in osmolarity 
(10), suggesting a functional link between 
the two channels. Interestingly, KIR4.1 
knock-out mice display impaired myeli-
nation of the spinal cord (11), and neu-
rophysiological studies have shown that 
potassium regulation through Kir4.1 is 
critical for signal transmission from the 
retina to the brain (12). Both spinal cord 
and optic nerve are commonly involved 
in MS and NMO.
The specific role of anti-KIR4.1 antibod-
ies in the pathogenesis of MS remains to be 
determined. Does astrocyte dysfunction con-
tribute to the inflammation and demyelinat-
ing in MS or could MS even reflect a primary 
astrocyte disturbance? Is MS indeed part of 
the growing group of channelopathies, akin 
to NMO? These are just some of the ques-
tions that arise from the identification of 
anti-KIR4.1 antibodies in MS patients.
The authors found no distinctive clini-
cal characteristics in the cohort of MS 
patients included in their study. Patients 
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 primary progressive MS tested positive for 
anti-KIR4.1 antibodies. Whether antibody 
production correlates with disease activity, 
or if anti-KIR4.1 antibody titers can help 
distinguish certain cohorts of MS patients 
will have to be addressed in future studies. 
We have learned that accurate distinction 
between MS and NMO is critical since the 
two conditions respond differently to cer-
tain immunotherapies. NMO can be exacer-
bated by interferon-beta and severe relapses 
have been reported in NMO patients treated 
with fingolimod and natalizumab (13); all 
three immunomodulators are approved MS 
treatments. On the other hand, many MS 
patients do not respond to plasma exchange 
and it is therefore desirable to identify 
patients who are likely to benefit from this 
treatment. It is conceivable that anti-KIR4.1 
antibody status will become an important 
factor to distinguish MS subpopulations 
and it may even emerge as a tool to guide 
treatment decisions.
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